Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis
Qingqing Jiang, Zhengtian Gu · 2026
Read Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis by Qingqing Jiang, Zhengtian Gu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13617617.txt.
Description
Qingqing Jiang and Zhengtian Gu compare treatments for a chronic nerve disease that slowly weakens the limbs, in a 2026 review. The disease, CIDP for short, arises when the immune system attacks the coating of the nerves. New drugs that block the neonatal Fc receptor, a protein that recycles antibodies, now compete with older options such as antibody infusions, steroids, plasma exchange, and rituximab.
The authors pooled 18 randomized trials with 2,184 patients and compared all the treatments against each other in one network analysis. Plasma exchange and steroids showed the highest chance of a clinical response. One of the new drugs, efgartigimod alfa, also beat placebo clearly and ranked best for improving grip strength. The review also weighs side effects and dropouts, and grades how much trust each comparison deserves, giving doctors a map of a fast-changing treatment field.
Catalog record
| CREATOR | Qingqing Jiang, Zhengtian Gu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |